Background and Purpose-To determine if severity of visually assessed white matter disease is associated with disability after ischemic stroke. 
arly and reliable estimation of functional outcome after ischemic stroke is important for developing treatment and rehabilitation regimens providing patients and family members with accurate prognoses for recovery and determining which patients are suitable for clinical trial enrollment. 1, 2 Leukoaraiosis, or white matter disease (WMD), can be detected as abnormal hypointensities on computed tomography and hyperintesities on T2-weighted or fluid-attenuated inversion recovery magnetic resonance imaging (MRI). 3 A common finding in the elderly, 4, 5 WMD has been shown to associate with recurrent stroke, 6, 7 cognitive decline, [8] [9] [10] gait disturbances, 11, 12 hemorrhagic transformation, 13 and functional outcome after ischemic stroke. [14] [15] [16] [17] Most studies have examined the relationship between functional stroke outcome and WMD severity using either computed tomography visual scales 14, 18, 19 or volumetric measurements. 15, 20 Although proposed to be more accurate than visual scales, 21 volumetric measurement of WMD lesions is time-intensive and not always available in the clinical setting. Whereas computed tomography is quick, it lacks the sensitivity that T2 and fluid-attenuated inversion recovery images offer. 22 Many MRI-compatible visual rating systems have been devised to quantify WMD severity. 23 The Fazekas 24 and Wahlund 22 visual scales both allow for quick assessment of WMD severity on T2 and fluid-attenuated inversion recovery images. We therefore sought to determine if the Fazekas and Wahlund visual rating scales predicted clinical stroke outcome after 1 year.
Subjects and Methods

Participants
This is a substudy of the Berlin "Cream & Sugar" Study (NCT 01378468), an ongoing prospective cohort study on the prognostic role of triglyceride and glucose levels in first ischemic stroke patients. Detailed Methods are presented in the online-only Data Supplement. 25 Briefly, we screened all male and female first-time acute ischemic stroke patients (3-7 days after symptom onset) older than 18 years of age who were admitted to 1 of 3 university campus hospitals in Berlin. Screening was conducted according to World Health Organization criteria and ischemic stroke was defined as a focal neurological deficit lasting for at least 24 hours with no signs of hemorrhage on cerebral imaging and was verified radiologically. Stroke was categorized according to a mechanism-based classification scheme (Trial of ORG 10172 in Acute Stroke Treatment [TOAST]). 26 All patients provided informed consent and the study was approved by local ethical committees.
Stroke severity was assessed 3 to 7 days after first ischemic stroke using the National Institute of Health Stroke Scale and modified Rankin Scale (mRS). The mRS was used to assess functional outcome after 1 year via telephone follow-up by a certified rater.
Blood Samples
Baseline data and venous blood samples were collected after participants had provided informed consent and fasted overnight for ≥12 hours. Fasting blood samples were drawn at 8:00 am. Triglyceride and cholesterol concentrations were determined in freshly drawn venous blood samples enzymatically using a Cobas 6000 analyzer (Roche/Hitachi). Glomerular filtration rate was estimated according to Takahashi Image Acquisition, WMD Severity Scales, and Stroke Lesion Volumes MRI was performed using 1.5-T (Avanto; Siemens Medical Solutions, Erlangen, Germany) and 3-T scanners (Tim Trio; Siemens AG, Erlangen, Germany). Two raters (C.L., N.I.) independently judged the MRI blinded to results of telephone follow-up and met for consensus in cases of disagreement. Fluid-attenuated inversion recovery or T2-weighted images were used to assess white matter lesion severity according to both the Wahlund 22 and Fazekas 24 classification systems. The Wahlund scale, or Age-Related White Matter Changes Scale, is a scale ranging from a score of 0 to 30 that takes into account both sides of the brain (right and left) and prespecified brain regions (frontal, parieto-occipital, temporal, infratentorial/cerebellum, and basal ganglia). Here, white matter hyperintensities are assigned a score of 0 to 3 in each region on both sides of the brain. The final score is the sum of all regions. The Fazekas scale is a scale ranging from 0 (no WMD) to 3 (high WMD) and only the MRI slice showing the most severe white matter lesions is rated (Figure) . Stroke lesion volumes were retrospectively analyzed using MRIcroN (version 12/2009; C. Rordens).
Statistical Analysis
Wahlund and Fazekas scores were stratified into 3 groups: mild (Wahlund score of 0-4; Fazekas: 0-1); moderate (Wahlund: 5-10; Fazekas: 2); and severe (Wahlund: >10; Fazekas: 3). 28 We also stratified follow-up mRS scores into 2 groups, without disability (0-1) and with disability (>1). Mann-Whitney U and Kruskal-Wallis tests were used to examine relationships between baseline and serum parameters, mRS at 1 year, and WMD severity (Fazekas and stratified Wahlund scores).
A 2-sided Fisher exact test was used to assess the relationship between stratified WMD and functional stroke outcome and mRS progression. If a significant relationship was found, then post hoc analyses using Sidak method were performed (level of significance at 0.017).
We performed a forward-stepping binary logistical regression analysis using the Hosmer-Lemeshow goodness of fit test. This analysis included all significant parameters (at the P<0.10 level) from the univariate analysis and the 3-level categorical variable WMD (stratified Wahlund scores or Fazekas). Bivariate graphical analysis revealed that relationships between National Institutes of Health Stroke Scale, eglomerular filtration rate, and disability after ischemic stroke were approximately linear. Serum glucose, insulin, glycosylated hemoglobin, creatinine, C-reactive protein, waist circumference, waist-to-hip ratio, and systolic blood pressure did not exhibit a linear relationship and were stratified into quartiles. Age was categorized by 5-year intervals starting at age 18 and ending at age 101 to incorporate all patients enrolled in our study. All statistical analyses were performed using SPSS 19.
Results
Between January 2009 and December 2010, 206 patients were included in the Berlin "Cream & Sugar" study. Of those, 154 needed follow-up by December 31, 2011 (date we closed our data collection for this substudy). We lost 26 patients to follow-up. Patients lost to follow-up had significantly lower (Fazekas) . Four patients (2 female; median age, 85 years; IQR, 80-92 years) died before 1-year follow-up (mRS score, 6). Cause of death in all 4 was unknown. No association was observed between WMD severity and death (Wahlund scores, P=0.566; Fazekas scores, P=0.093). Baseline characteristics were similar using Fazekas and stratified Wahlund scores. The only difference we observed was that patients with low Fazekas scores, ie, mild WMD, had significantly lower creatinine levels. This finding was observed as a trend when WMD was assessed using stratified Wahlund scores.
Stroke lesion volumes were retrospectively analyzed for all 101 patients, were normally distributed (KolmogorovSmirnov), and had a mean volume of 6.5 mL (standard deviation, 14.1).
As expected, Wahlund and Fazekas scores correlated significantly (Kendall-τ-b, 0.7; P<0.01). The median Wahlund scores of patients with a Fazekas score of 1, 2, or 3 was 1 (IQR, 0-3), 6 (IQR, 5-10), and 11.5 (IQR, 8.8-17), respectively. MRI findings, stroke subtypes, and outcomes are compared in the online-only Data Supplement.
Two forward-stepping binary logistical regression analyses including age (5- 
Discussion
In this study, we found that visually assessed WMD is associated with: (1) baseline mRS; (2) follow-up mRS; and (3) increase in mRS (Fazekas scale only; data not shown). Both the Wahlund and Fazekas visual rating scales are useful in making this assessment with MRI. These results confirm those of Kissela et al, 29 who used a method similar to the Fazekas rating scale to assess short-term (3-month) functional outcome after ischemic stroke. They also confirm the results of Samuelsson et al, 30 who specifically looked at lacunar infarct patients, and of Arsava et al, 15 who used diffusion-weighted imaging volumetry and computed tomography images in 240 acute ischemic stroke patients to assess WMD severity after 6 months. The impetus for volumetric quantification of white matter lesions in relation to functional stroke outcome originally stemmed from earlier conflicting studies, most of which used computed tomography-based visual scales.
14 In these studies, only some found a positive relationship, 15, [31] [32] [33] whereas others found none to exist. 34, 35 We agree that a quantification of WMD severity through volumetric measurement has advantages to a visual scale. However, volumetric measurement often takes time and requires special software packages. As our results show, visual scales like those of Fazekas and Wahlund may be sufficient for estimating clinical outcome after stroke. Except Tei et al, 33 who included 132 posterior circulation infarct patients, each of these mentioned trials included >220 patients with WMD. In this study, we were able to show the prognostic use of visual scales in a sample as small as 101 patients.
The Fazekas and Wahlund rating scales each have drawbacks. They correlated to a certain extent. However, Fazekas scores are based more on lesion size rather than on location distribution like Wahlund scores. Therefore, a patient with a low Fazekas score may simultaneously have a high Wahlund score or vice versa. Although more anatomically precise than the Fazekas scale, the Wahlund system is more time-intensive and requires closer evaluation of individual brain regions. 36 Arteriolar sclerosis, 37 ie, small vessel disease, and venous collagenosis 38 may contribute to WMD pathogenesis. In our study, glucose, an established risk factor for arteriolar sclerosis, 38 associated with disability after ischemic stroke and WMD severity. Glycosylated hemoglobin also is associated with outcome and WMD. This supports the hypothesis that WMD is influenced by small vessel pathology. The observed association between WMD and creatinine may be indicative of similar renal and cerebral small vessel pathologies.
A large prospective cohort study found that C-reactive protein was associated with WMD. 39 In our study, C-reactive protein was associated with functional outcome, but not with WMD severity. Although not significant, median C-reactive protein values increased with each tertile increase in WMD severity. Our study was relatively small and some participants had very high C-reactive protein levels. It is possible that results pertaining to C-reactive protein were influenced by outliers. Most of our patient sample (64%) had excellent outcome (mRS score, 0-1), making it difficult to assess accuracy of outcome prediction in severe cases. This is an additional limitation of our study, because our stroke group generally consisted of very mild (National Institutes of Health Stroke Scale range from 0-24 on hospital admission and 0-8 at time of testing) lacunar strokes. Moreover, fasting insulin levels differed between patients who completed follow-up and those who did not, so the issue of potential drop-out bias cannot be excluded.
It also has been suggested that WMD might be a form of end-organ damage and that antihypertensive therapy can slow its progression. 40 Unlike previous findings, 41, 42 our results showed that elevated systolic, but not diastolic, blood pressure associates with worse functional outcome but not with WMD severity. This underscores the possible heterogeneity of WMD pathogenesis and progression.
In conclusion, we evaluated the usefulness of 2 visual WMD rating scales using MRI as a method to estimate functional stroke outcome after 1 year. Both the Fazekas and Wahlund scales were associated with functional stroke outcome and may offer clinicians a quick way to estimate functional outcome in acute ischemic stroke patients.
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Supplemental Tables   Table S1 . Inclusion/exclusion criteria for the Berlin "Cream&Sugar" Study. NIHSS indicates National Institute of Health Stroke Score; mRS, modified Rankin Scale; eGFR, estimated glomerular filtration rate; BP, blood pressure; LDL, low density lipoprotien; HbA1c, glycosylated hemoglobin; WMD, white matter disease. *Fischer's exact test followed by Sidak's post hoc method (if significant).
Inclusion
†Kruskal-Wallis test. ‡Values are n (%). §As a model, "Other" differed significantly from "Cardioembolic" strokes, p=.039 (Sidak's post hoc method).
